A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 256 participants.
Also called NCT07660796
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 256 participants
- Registry
-
NCT07660796
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07660796. Randomized; double masking; primary purpose treatment. Start 2026-07-06 (anticipated); primary completion 2027-10-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Condition
- Hypertension
- Intervention (Drug)
- HCP1803-3
- Intervention (Drug)
- HCP1803-4
- Intervention (Drug)
- RLD2001-1
- Intervention (Drug)
- RLD2001-2
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct07660796- Content hash
7b7f55290f70dc8960549dfdcf036be44f9f9f3351efc14b006a636b00b31817